TME Pharma NV

ALTME

Company Profile

  • Business description

    TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).

  • Contact

    Max-Dohrn-Street 8-10
    Berlin10589
    DEU

    T: +49 30166370820

    https://www.tmepharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    13

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,586.7015.300.18%
CAC 407,734.40130.04-1.65%
DAX 4023,629.58369.59-1.54%
Dow JONES (US)41,603.07256.02-0.61%
FTSE 1008,717.9721.29-0.24%
HKSE23,601.2656.950.24%
NASDAQ18,737.21188.53-1.00%
Nikkei 22537,160.47174.600.47%
NZX 50 Index12,596.5065.75-0.52%
S&P 5005,802.8239.19-0.67%
S&P/ASX 2008,360.9012.200.15%
SSE Composite Index3,348.3731.82-0.94%

Market Movers